US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Floating Rate Municipal Income ETF

24.86

+0.02930.12%

Volume:2K

Turnover:54.96K

Market Cap:31.07M

PE:- -

High:24.86

Open:24.82

Low:24.82

Close:24.83

52wk High:25.00

52wk Low:24.62

Shares:1.25M

Float Shares:1.25M

Volume Ratio:1.04

T/O Rate:0.18%

Dividend:0.55

Dividend Rate:2.22%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/PVI"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"PVI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVI\",,,,,undefined,":{"symbol":"PVI","market":"US","secType":"STK","nameCN":"Invesco Floating Rate Municipal Income ETF","latestPrice":24.8593,"timestamp":1787683794147,"preClose":24.83,"halted":0,"volume":2213,"delay":0,"changeRate":0.0011800241643174696,"floatShares":1250000,"shares":1250000,"eps":0,"marketStatus":"Trading","change":0.0293,"latestTime":"08-25 15:08:24 EDT","open":24.82,"high":24.8593,"low":24.82,"amount":54960.642828000004,"amplitude":0.001583,"askPrice":24.96,"askSize":100,"bidPrice":24.7,"bidSize":2100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.83,"sharesOutstanding":1250000,"nav":24.85203,"aum":31065037.5,"dividendRate":0.022173,"bidAskSpread":0.003069,"postHourTrading":{"tag":"盘后","latestPrice":25.122,"preClose":24.83,"latestTime":"16:57 EDT","volume":1077,"amount":26885.129,"timestamp":1787605052741,"change":0.292,"changeRate":0.01176,"amplitude":0.015087},"volumeRatio":1.040939},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVI\",,,,,undefined,":{"symbol":"PVI","floatShares":1250000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.040939,"shares":1250000,"dividePrice":0.5512,"high":24.8593,"amplitude":0.001583,"preClose":24.83,"low":24.82,"week52Low":24.62,"pbRate":"--","week52High":25,"institutionHeld":0,"latestPrice":24.8593,"committee":0.909091,"eps":0,"divideRate":0.022173,"volume":2213,"delay":0,"ttmEps":0,"open":24.82,"prevYearClose":24.92,"prevWeekClose":24.885,"prevMonthClose":24.83,"prevQuarterClose":24.885,"fiveDayClose":24.855,"twentyDayClose":24.79,"sixtyDayClose":24.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVI\",params:#limit:5,,,undefined,":[{"date":"2026-08-24","symbol":"PVI","amount":0.04478,"announcedDate":"2026-08-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-24","defaultRemindTime":1787578200000,"name":"Invesco Floating Rate Municipal Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-28","payableDate":"2026-08-24","currency":"USD","dateTimestamp":1787544000000,"payDate":"2026-08-28"},{"date":"2026-07-20","symbol":"PVI","amount":0.04567,"announcedDate":"2026-07-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-20","defaultRemindTime":1784554200000,"name":"Invesco Floating Rate Municipal Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-24","payableDate":"2026-07-20","currency":"USD","dateTimestamp":1784520000000,"payDate":"2026-07-24"},{"date":"2026-06-22","symbol":"PVI","amount":0.04122,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Floating Rate Municipal Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-05-18","symbol":"PVI","amount":0.05864,"announcedDate":"2026-05-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-18","defaultRemindTime":1779111000000,"name":"Invesco Floating Rate Municipal Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-22","payableDate":"2026-05-18","currency":"USD","dateTimestamp":1779076800000,"payDate":"2026-05-22"},{"date":"2026-04-20","symbol":"PVI","amount":0.03797,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-20","defaultRemindTime":1776691800000,"name":"Invesco Floating Rate Municipal Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-24","payableDate":"2026-04-20","currency":"USD","dateTimestamp":1776657600000,"payDate":"2026-04-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVI\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-15","recordDate":"2016-09-19","paymentDate":"2016-09-30","value":0.00389,"currency":"USD"},{"executeDate":"2016-10-14","recordDate":"2016-10-18","paymentDate":"2016-10-31","value":0.01105,"currency":"USD"},{"executeDate":"2016-11-15","recordDate":"2016-11-17","paymentDate":"2016-11-30","value":0.00789,"currency":"USD"},{"executeDate":"2016-12-15","recordDate":"2016-12-19","paymentDate":"2016-12-30","value":0.0066,"currency":"USD"},{"executeDate":"2017-01-13","recordDate":"2017-01-18","paymentDate":"2017-01-31","value":0.01084,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVI\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633948400","title":"Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948400","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948400?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287696/0/en/Microbot-Medical-s-LIBERTY-Endovascular-Robotic-System-is-Now-Adopted-by-Multiple-Accounts-Across-Key-Territories-Including-Two-ACCESS-PVI-Pivotal-Clinical-Trial-Sites.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0124384867.USD","SIR","LU0256863811.USD","BK4588","BK4082","IR","BK4161","BK4585","PVI","LU0417517546.SGD","SG9999001440.SGD","LU1978683503.SGD","MBOT","LU0256863902.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609538908","title":"Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609538908","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609538908?lang=en_us&edition=fundamental","pubTime":"2026-02-06 06:40","pubTimestamp":1770331200,"startTime":"0","endTime":"0","summary":"Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field AblationCARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation  solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston.The FieldForce Ablation System by Field Medical. A focal PFA system designed to support transmural lesion creation for complex cardiac arrhythmias.These findings extend Field Medical's body of clinical evidence of its high-voltage focal PFA approach beyond ventricular arrhythmias and into the development of therapy for atrial fibrillation . Together with previously reported six-month first-in-human ventricular tachycardia  data, the results support the emergence of a versatile ablation p","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2878123/Field_Medical_Ablation_System.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2878123/Field_Medical_Ablation_System.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/field-medical-presents-late-breaking-field-pulse-trial-data-at-af-symposium-2026-302680670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVI","VT","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591649326","title":"Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649326","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649326?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:30","pubTimestamp":1765801800,"startTime":"0","endTime":"0","summary":"Data from FDA-advised study demonstrates Lumee Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with tra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205315/0/en/Profusa-U-S-Study-Met-Primary-End-Points-as-Presented-at-Late-Breaking-Clinical-Trials-at-Paris-Vascular-Insights-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCOM","PVI","BK4122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585462209","title":"Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462209?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:15","pubTimestamp":1763990100,"startTime":"0","endTime":"0","summary":"Study evaluates Lumee Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO) in peripheral artery disease patients BERKELEY, Calif, Nov.  24, 2025  (GLOBE NEWSWIRE) --","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193475/0/en/Profusa-to-Present-Late-Breaking-U-S-Based-Clinical-Trial-Update-at-Paris-Vascular-Insights-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PVI\",params:#limit:6,delay:false,,,undefined,":[]}}